Respiratory care products manufacturer Maxtec has received approval from the US Food and Drug Administration (FDA) for its new oxygen and pressure monitor, MaxO2 ME+p.
With this approval, the MaxO2 ME+p device is now available in the US.
The new oxygen-monitoring device comes with integrated pressure monitoring to enable healthcare providers to continuously monitor the concentration of oxygen and pressure being administered to patients.
The device can be used for all age groups from newborns to adults.
Maxtec is engaged in the development of innovative respiratory solutions for patients and clinicians. It operates as part of Perma Pure Group.
Perma Pure Group president and CEO Kathy Ouellette said: “This device is the result of our ongoing commitment to developing innovative medical devices that make a real difference in the lives of patients and healthcare providers.
“We believe that the MaxO2 ME+p is a game-changer in the field and we are excited to see the impact it will have on patient care.”
Clinicians can use the device to gather crucial data required for providing effective care to patients.
The real-time, accurate data on oxygen concentration and pressure ensure patients receive the correct treatment.
The device can also be used with a bubble continuous positive airway pressure therapy setup in a neonatal intensive care unit setting.
The company comprises a vast product portfolio that includes oxygen sensors, flow sensors, analysers and flow meters.